Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Nicholas Kitchin

7PUBLICATIONS
14CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Evolution of developmental systemsInfant and child healthMedical molecular engineering of nucleic acids and proteinsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

Sort by Publication Date:
|May 25, 2026
Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B <i>Clostridioides difficile</i> Vaccine in Adults 50 Years and Older.

|Jan 21, 2026
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.

Patricia Winokur, Oyeniyi Diya, David Fitz-Patrick

|Dec 08, 2025
T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children.

Isabel Vogler, Stephanie Renken, Rolf Hilker

|May 07, 2025
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults.

Angela Branche, Mark J Mulligan, Alok Maniar

|Feb 26, 2025
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age.

Joel M Neutel, Rahsan Erdem, Qin Jiang

|Jul 27, 2024
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.

Juleen Gayed, Vishva Bangad, Xia Xu

Pageof 2

Frequent Collaborators

3 joint publications

William C Gruber

2 joint publications

Kena A Swanson

2 joint publications

Stephen P Lockhart

1 joint publications

Xuping Xie

1 joint publications

Rahsan Erdem

1 joint publications

Qin Jiang

1 joint publications

Alok Maniar

1 joint publications

Islamiat Oladipupo

1 joint publications

Andrew Finlayson

1 joint publications

Patricia Winokur

Frequent Collaborators

3 joint publications

William C Gruber

2 joint publications

Kena A Swanson

2 joint publications

Stephen P Lockhart

1 joint publications

Xuping Xie